Silence Therapeutics (LON:SLN) announced its earnings results on Tuesday. The company reported GBX (12.40) (($0.16)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%.

LON:SLN traded up GBX 0.50 ($0.01) on Thursday, hitting GBX 144.50 ($1.88). The stock had a trading volume of 400 shares, compared to its average volume of 13,380. Silence Therapeutics has a 52-week low of GBX 71.88 ($0.94) and a 52-week high of GBX 254.75 ($3.32).

Separately, Peel Hunt reissued a “buy” rating on shares of Silence Therapeutics in a research report on Tuesday.

Silence Therapeutics Company Profile

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Read More: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.